利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.014 秒)

    IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS
    1.
    发明申请
    IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS 审中-公开

    公开(公告)号：WO2023076820A1

    公开(公告)日：2023-05-04

    申请号：PCT/US2022/078297

    申请日：2022-10-18

    申请人： NAVICURE BIOPHARMACEUTICALS LIMITED ,  SAUNDERS, Paul

    发明人： WU, Chia-Mao

    IPC分类号： A61K39/12 ,  C07K14/005 ,  A61P31/12 ,  C07K16/10 ,  C12N7/00

    摘要： Immunogenic fusion proteins against coronavirus. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of SARS-CoV2; a translocation domain located between the CD40-binding domain and the antigen, and a furin and/or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. In one embodiment, the translocation domain is a Shiga toxin (Stx) translocation peptide, and the antigen is located at the N-terminal of the fusion protein. In another embodiment, the translocation domain is a Pseudomonas Exotoxin A (PE) translocation peptide, and the CD40-binding domain is located at the N-terminal of the fusion protein. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, and/or for reducing, inhibiting, treating and/or ameliorating symptoms caused by SARS-CoV2 infection in a subject in need thereof.

    4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF
    2.
    发明申请
    4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF 审中-公开

    公开(公告)号：WO2021086689A1

    公开(公告)日：2021-05-06

    申请号：PCT/US2020/056515

    申请日：2020-10-20

    申请人： PRIME REACH TRADING LIMITED ,  SAUNDERS, Paul

    发明人： CHOU, Yu-Cheng

    IPC分类号： A61K31/437 ,  C07D471/04 ,  C07D471/14

    摘要： 4-Amino-imidazoquinoline compounds and use thereof are disclosed. The compounds of the invention are Toll-like receptor 7 (TLR7) and TLR8 dual agonists, which exhibit activities in inducing IL-12 and IP-10 expression without over-inducing IL-6. The TLR 7/8 dual agonists are potentially useful medications as immune response modifiers. Use of a compound or salt thereof according to the invention in the manufacture of a medicament for treating a disease or a condition wherein activation of TLR7 and/or TLR8 provides a benefit in a subject in need thereof is disclosed. A compound or a pharmaceutical composition for use in treating a viral infection, cancer, and/or an allergic disease, or for use in activating immune responses that are effective against a viral infection, a tumor, and/or an allergic disease in a subject in need thereof is also disclosed.

    SENSING METHOD, SENSOR AND METHOD OF MANUFACTURING THE SAME
    5.
    发明申请
    SENSING METHOD, SENSOR AND METHOD OF MANUFACTURING THE SAME 审中-公开

    公开(公告)号：WO2019209366A1

    公开(公告)日：2019-10-31

    申请号：PCT/US2018/054784

    申请日：2018-10-08

    申请人： NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  SAUNDERS, Paul

    发明人： CHU, Jinn P. ,  CHEN, Chien-Kuang

    IPC分类号： A61B5/053 ,  B01L3/00 ,  C01B32/15 ,  C01B32/158 ,  C01B32/168 ,  G01N27/26

    摘要： A method of manufacturing a sensor comprises: providing a substrate; forming a photoresist layer on the substrate, wherein the photoresist layer comprises a hole array which comprises a plurality of holes which pass through from one side of the photoresist layer to the substrate; sputtering a metallic glass material on the photoresist layer to deposit the metallic glass material on a hole wall of each hole and a part of the substrate defined by the hole wall; removing the photoresist layer and forming a nanotube array structure of the metallic glass material, wherein the nanotube array structure comprises a plurality of nanotubes, and each nanotube has an open end opposite to the substrate; performing a surface treatment on the nanotube array structure to form a plurality of functional groups in each nanotube; and anchoring a plurality of aptamers in each nanotube by activating the plurality of functional groups.

    SELF-METERING SYSTEM AND TESTING DEVICE WITH CASING AND SLIDING MEMBER TO CUT-OFF AND SET SAMPLE VOLUME
    6.
    发明申请
    SELF-METERING SYSTEM AND TESTING DEVICE WITH CASING AND SLIDING MEMBER TO CUT-OFF AND SET SAMPLE VOLUME 审中-公开
    自动测量系统和测试设备，具有切割和设置样品量的滑动部件

    公开(公告)号：WO2011088582A1

    公开(公告)日：2011-07-28

    申请号：PCT/CA2011/050043

    申请日：2011-01-25

    申请人： CARDIOGENICS INC. ,  THOROGOOD, Stephen Daniel ,  SAUNDERS , Paul

    发明人： THOROGOOD, Stephen Daniel ,  SAUNDERS , Paul

    IPC分类号： G01N33/48 ,  G01N35/00

    CPC分类号： G01N21/78 ,  B01L3/502 ,  B01L3/508 ,  B01L2200/0605 ,  B01L2200/141 ,  B01L2300/045

    摘要： A testing cartridge for metering of a sample to be tested. The testing cartridge includes a casing defining a casing opening and a sliding member defining a sliding member opening. The casing opening or the sliding member opening can define a specified volume, wherein the casing opening and the sliding member opening collectively define a sample application region dimensioned to accommodate receiving an amount of sample exceeding the specified volume. The sliding member is movable transversely to the casing opening by having the sliding member and the casing traverse across each other's respective openings to remove excess sample from the received amount of sample and retain the specified volume from the received amount of sample.

    摘要翻译： 用于测量待测试样品的测试盒。 测试盒包括限定壳体开口的壳体和限定滑动构件开口的滑动构件。 壳体开口或滑动构件开口可以限定特定的体积，其中壳体开口和滑动构件开口共同地限定样品施加区域，其尺寸被设计成适应接收超过指定体积的样品量。 滑动构件通过使滑动构件和壳体横过彼此的开口而横向于壳体开口移动，以从接收量的样品中除去多余的样品，并从接收量的样品中保留指定体积。

    SURFACE EGRESS AND/OR INGRESS HOUSING
    8.
    发明申请
    SURFACE EGRESS AND/OR INGRESS HOUSING 审中-公开
    表面轮胎和/或动感外壳

    公开(公告)号：WO2008129247A1

    公开(公告)日：2008-10-30

    申请号：PCT/GB2008/001334

    申请日：2008-04-16

    申请人： GKN AEROSPACE SERVICES LIMITED ,  SAUNDERS, Paul, Vincent

    发明人： SAUNDERS, Paul, Vincent

    IPC分类号： G02B6/38

    CPC分类号： G02B6/3897 ,  G02B6/3825 ,  G02B6/3849

    摘要： A surface egress and/or ingress housing is provided for an elongate flexible member. A front opening in a front surface of the housing can receive a connector for the elongate flexible member. A base of the housing can be at least partially received under an embedding layer for mounting the housing on the surface. An internal cavity in the housing can communicate with the front opening and with a rear opening in the base. The rear opening and the cavity can be wider than the elongate flexible member to facilitate mounting of the housing.

    摘要翻译： 为细长的柔性构件设置表面出口和/或入口外壳。 壳体的前表面中的前开口可以容纳用于细长柔性构件的连接器。 壳体的底部可以至少部分地容纳在用于将壳体安装在表面上的嵌入层下面。 外壳中的内腔可以与前开口连通，并在基座中与后开口连通。 后开口和空腔可以比细长的柔性构件更宽以便于安装壳体。

    FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES
    9.
    发明申请
    FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES 审中-公开

    公开(公告)号：WO2021225820A1

    公开(公告)日：2021-11-11

    申请号：PCT/US2021/029203

    申请日：2021-04-26

    申请人： NAVICURE BIOPHARMACEUTICALS LIMITED ,  SAUNDERS, Paul

    发明人： WU, Chia-Mao

    IPC分类号： C07K16/28

    摘要： Fusion proteins for immunotherapy against cancer and infectious diseases are disclosed. A fusion protein according to the invention comprises a CD40-binding domain; an antigen; and a translocation domain located between the CD40-binding domain and the antigen, in which a furin and/or cathepsin L cleavage site is present in the fusion protein between the CD40-binding domain and the translocation domain. The antigen is an antigen of a pathogen or a tumor antigen. The furin and/or cathepsin L cleavage site permits removal of the CD40-binding domain away from the fusion protein via furin and/or cathepsin L cleavage. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, treating a tumor and/or a disease caused by a pathogen in a subject in need thereof.

    IMMUNOGENIC FUSION PROTEINS AGAINST INFECTIOUS ANIMAL DISEASES
    10.
    发明申请
    IMMUNOGENIC FUSION PROTEINS AGAINST INFECTIOUS ANIMAL DISEASES 审中-公开

    公开(公告)号：WO2023081595A1

    公开(公告)日：2023-05-11

    申请号：PCT/US2022/078832

    申请日：2022-10-28

    申请人： NAVICURE BIOPHARMACEUTICALS LIMITED ,  SAUNDERS, Paul

    发明人： WU, Chia-Mao

    IPC分类号： A61K38/17 ,  A61K38/16 ,  C07K14/705 ,  C07K14/21 ,  C07K14/18 ,  A61K38/1774 ,  A61K38/162

    摘要： Immunogenic fusion proteins against infectious animal diseases. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of a pathogen; a translocation domain located between the CD40-binding domain and the antigen, and a furin and/or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, or for reducing, inhibiting, treating and/or ameliorating an infectious animal disease caused by a pathogen in an animal in need thereof